<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Lipid Modification â€“ CVD Prevention â€¢ Quick Algorithm</title>
  <meta name="description" content="Oneâ€‘page quick reference algorithm for lipid modification in primary and secondary prevention of CVD (NICE CKSâ€‘aligned)." />
  <style>
    :root{
      --bg: #0b1020;
      --bg-muted:#0f1630;
      --card:#121936;
      --text:#ecf1ff;
      --muted:#b9c3ff;
      --accent:#7aa2ff;
      --accent-2:#61d4a9;
      --warn:#ffd166;
      --danger:#ff6b6b;
      --shadow: 0 10px 28px rgba(0,0,0,.35);
      --radius: 18px;
      --surface: linear-gradient(180deg, rgba(255,255,255,.06), rgba(255,255,255,.02));
    }
    @media (prefers-color-scheme: light){
      :root{
        --bg:#f6f7fb; --bg-muted:#eef2ff; --card:#ffffff; --text:#11131a; --muted:#4d5a7d; --accent:#356bf6; --accent-2:#0e9f6e; --warn:#b7791f; --danger:#e11d48; --shadow:0 10px 24px rgba(20,39,129,.12)
      }
    }
    *{box-sizing:border-box}
    html,body{height:100%}
    body{
      margin:0; font-family: ui-sans-serif, system-ui, -apple-system, Segoe UI, Roboto, Helvetica Neue, Arial, Noto Sans, Apple Color Emoji, Segoe UI Emoji;
      background: radial-gradient(1200px 600px at 20% -10%, rgba(122,162,255,.18), transparent 60%), radial-gradient(1200px 600px at 120% -20%, rgba(97,212,169,.20), transparent 60%), var(--bg);
      color:var(--text); line-height:1.55;
    }
    .wrap{max-width:1100px; margin-inline:auto; padding:28px 22px 80px}
    header{
      position:sticky; top:0; z-index:50; backdrop-filter:saturate(140%) blur(8px);
      background: color-mix(in srgb, var(--bg) 86%, transparent);
      border-bottom:1px solid color-mix(in srgb, var(--text) 10%, transparent);
    }
    .head-inner{max-width:1100px; margin:0 auto; padding:16px 22px; display:flex; align-items:center; gap:18px; justify-content:space-between}
    .brand{display:flex; gap:14px; align-items:center}
    .logo{width:40px; height:40px; border-radius:12px; background:
      conic-gradient(from 180deg at 50% 50%, var(--accent), var(--accent-2) 50%, var(--accent) 100%);
      box-shadow: var(--shadow);
      outline: 2px solid color-mix(in srgb, var(--text) 10%, transparent);
    }
    h1{margin:0; font-weight:800; letter-spacing:.2px; font-size: clamp(1.15rem, 1rem + 1vw, 1.6rem)}
    .sub{opacity:.8; font-size:.92rem}
    .actions{display:flex; gap:10px}
    .btn{appearance:none; border:0; padding:9px 13px; border-radius:12px; cursor:pointer; font-weight:650; background:var(--card); color:var(--text); box-shadow: var(--shadow);
      border:1px solid color-mix(in srgb, var(--text) 10%, transparent); display:inline-flex; align-items:center; gap:8px}
    .btn:hover{transform:translateY(-1px)}
    .btn:active{transform:translateY(0)}
    .print{background: linear-gradient(180deg, var(--accent), color-mix(in srgb, var(--accent) 40%, black));}

    .hero{margin-top:26px; padding:20px; background:var(--bg-muted); border:1px solid color-mix(in srgb, var(--text) 10%, transparent); border-radius: 20px; box-shadow: var(--shadow)}
    .hero h2{margin:0 0 6px 0; font-size:clamp(1.2rem, 1.1rem + 1vw, 1.6rem)}
    .chips{display:flex; flex-wrap:wrap; gap:8px; margin-top:10px}
    .chip{font-weight:700; letter-spacing:.25px; font-size:.82rem; padding:6px 10px; border-radius:999px; border:1px solid color-mix(in srgb, var(--text) 12%, transparent); background:var(--surface)}
    .chip.ok{background:linear-gradient(180deg, color-mix(in srgb, var(--accent-2) 30%, transparent), transparent); border-color: color-mix(in srgb, var(--accent-2) 50%, transparent)}
    .chip.warn{background:linear-gradient(180deg, color-mix(in srgb, var(--warn) 25%, transparent), transparent); border-color: color-mix(in srgb, var(--warn) 45%, transparent)}

    .grid{display:grid; gap:16px; grid-template-columns: repeat(auto-fit, minmax(290px, 1fr)); margin-top:18px}
    .card{background:var(--card); border-radius: var(--radius); padding:18px 18px; box-shadow: var(--shadow); border:1px solid color-mix(in srgb, var(--text) 10%, transparent)}
    .card h3{margin:2px 0 10px 0; font-size:1.05rem}
    .kicker{font-size:.78rem; letter-spacing:.22em; text-transform:uppercase; color:var(--muted); font-weight:800}
    ul{margin:8px 0 0 0; padding-left:20px}
    li{margin:6px 0}
    .inline-badge{padding:2px 8px; border-radius:999px; background:var(--surface); border:1px solid color-mix(in srgb, var(--text) 12%, transparent); font-weight:700; font-size:.78rem}
    .two-col{display:grid; grid-template-columns:1fr; gap:16px}
    @media(min-width:880px){.two-col{grid-template-columns:1.2fr .8fr}}

    table{width:100%; border-collapse:collapse; font-size:.95rem; border:1px solid color-mix(in srgb, var(--text) 10%, transparent)}
    th, td{padding:10px 12px; border-bottom:1px solid color-mix(in srgb, var(--text) 10%, transparent)}
    th{text-align:left; background:var(--bg-muted)}

    details{border:1px dashed color-mix(in srgb, var(--text) 22%, transparent); border-radius:14px; padding:12px 14px}
    summary{cursor:pointer; font-weight:800}

    .footer{margin-top:22px; opacity:.8; font-size:.85rem}

    .pill-list{display:flex; flex-wrap:wrap; gap:8px}
    .pill{border:1px solid color-mix(in srgb, var(--text) 12%, transparent); background:var(--surface); border-radius:999px; padding:7px 10px; font-weight:650; font-size:.88rem}

    .note{font-size:.9rem; padding:10px 12px; border-radius:12px; background:linear-gradient(180deg, rgba(255,255,255,.04), transparent); border:1px solid color-mix(in srgb, var(--text) 12%, transparent)}

    .callout{display:flex; gap:10px; align-items:center; padding:10px 12px; border-radius:12px; background:linear-gradient(180deg, rgba(255,255,255,.05), transparent); border:1px solid color-mix(in srgb, var(--text) 12%, transparent)}
    .callout .dot{width:10px; height:10px; border-radius:999px; background:var(--accent)}

    .tip{font-size:.9rem; opacity:.9}

    @media print{
      header{display:none}
      body{background:white; color:black}
      .card, .hero{box-shadow:none; border:1px solid #00000020}
      .btn{display:none}
      .chip{background:transparent}
      a::after{content:" (" attr(href) ")"; font-size:.8em}
    }
  </style>
</head>
<body>
  <header>
    <div class="head-inner">
      <div class="brand">
        <div class="logo" aria-hidden="true"></div>
        <div>
          <h1>Lipid Modification â€“ CVD Prevention</h1>
          <div class="sub">Quick reference algorithm for busy clinics</div>
        </div>
      </div>
      <div class="actions">
        <button class="btn print" onclick="window.print()" title="Print this page">
          ğŸ–¨ï¸ <span>Print</span>
        </button>
        <button class="btn" id="toggleTheme" title="Toggle dark / light">
          ğŸŒ“ <span>Theme</span>
        </button>
      </div>
    </div>
  </header>

  <main class="wrap">

    <section class="hero">
      <h2>Atâ€‘aâ€‘glance</h2>
      <p class="tip">Primary: <span class="inline-badge">Atorvastatin 20 mg</span> â†’ aim <strong>â‰¥40% â†“ nonâ€‘HDL</strong>. Secondary: <span class="inline-badge">Atorvastatin 80 mg</span> â†’ aim <strong>LDL â‰¤2.0</strong> or <strong>nonâ€‘HDL â‰¤2.6 (mmol/L)</strong>. Addâ€‘on sequence if above target or intolerant: <strong>Optimize statin â†’ + Ezetimibe â†’ + Bempedoic acid â†’ Injectable (Inclisiran / PCSK9)</strong>. Consider <strong>Icosapent ethyl</strong> (secondary) where eligible.</p>
      <div class="chips" role="list">
        <div class="chip ok" role="listitem">Nonâ€‘fasting lipids ok</div>
        <div class="chip ok" role="listitem">CK only if symptomatic</div>
        <div class="chip warn" role="listitem">Avoid statins in pregnancy / breastfeeding</div>
        <div class="chip" role="listitem">Agree higher doses with renal team if eGFR &lt;30</div>
      </div>
    </section>

    <section class="grid" aria-label="Algorithm grid">

      <article class="card two-col" aria-labelledby="who-title">
        <div>
          <div class="kicker">1 Â· Eligibility</div>
          <h3 id="who-title">Who to Treat</h3>
          <ul>
            <li><strong>Primary prevention</strong>: QRISK3 â‰¥10% (incl. type 2 diabetes).</li>
            <li><strong>No calculator needed</strong>: type 1 diabetes (â‰¥40y, or â‰¥10y duration, or nephropathy / other RFs); CKD (eGFR &lt;60 and/or albuminuria); familial hypercholesterolaemia.</li>
            <li><strong>Consider</strong>: age â‰¥85 (individualised, incl. frailty, preferences).</li>
            <li><strong>Secondary prevention</strong>: all with established CVD (CHD, stroke/TIA, PAD, aortic disease).</li>
          </ul>
          <div class="note" style="margin-top:10px">Risk tools may <em>underestimate</em> risk in: people with HIV, on meds causing dyslipidaemia (e.g., antipsychotics, steroids, immunosuppressants), severe mental illness, autoimmune / inflammatory disorders, recent exâ€‘smokers.</div>
        </div>
        <div>
          <div class="kicker">Baseline</div>
          <ul>
            <li>Nonâ€‘fasting full lipid profile; ALT/AST; HbA1c/glucose; renal function.</li>
            <li>CK <em>only</em> if unexplained muscle symptoms. If CK &gt;5Ã— ULN â†’ do not start / stop statin; reâ€‘check.</li>
            <li>Assess secondary causes &amp; FHx. If <strong>TC &gt;9.0</strong> or <strong>nonâ€‘HDL &gt;7.5</strong> â†’ specialist assessment.</li>
            <li><strong>Triglycerides</strong>: &gt;20 â†’ urgent specialist; 10â€“20 â†’ repeat fasting 5â€“14 days &amp; seek advice if &gt;10 persists; 4.5â€“9.9 â†’ other RFs may be underestimated.</li>
          </ul>
        </div>
      </article>

      <article class="card" aria-labelledby="start-title">
        <div class="kicker">2 Â· Firstâ€‘line treatment</div>
        <h3 id="start-title">Initial Statin</h3>
        <ul>
          <li><strong>Primary</strong> â†’ <strong>Atorvastatin 20 mg once daily</strong> (CKD included).</li>
          <li><strong>Secondary</strong> â†’ <strong>Atorvastatin 80 mg once daily</strong> (use lower dose if interactions, adverseâ€‘effect risk, CKD with eGFR&lt;60, or patient preference).</li>
          <li>If statin contraindicated or not tolerated â†’ <strong>Ezetimibe monotherapy</strong> (secondary: offer regardless of baseline lipids).</li>
          <li class="tip">Dosing time: atorvastatin any time; simvastatin / pravastatin / fluvastatin in evening.</li>
        </ul>
        <div class="note">Shared decisionâ€‘making: discuss benefits/risks, lifestyle, comorbidities, drug interactions (e.g., grapefruit juice), and reproductive plans (stop statins 3 months before conception; avoid in pregnancy &amp; breastfeeding).</div>
      </article>

      <article class="card" aria-labelledby="targets-title">
        <div class="kicker">3 Â· Treatment goals</div>
        <h3 id="targets-title">Targets</h3>
        <table aria-label="Lipid targets">
          <thead><tr><th>Setting</th><th>Target</th></tr></thead>
          <tbody>
            <tr><td>Primary prevention</td><td><strong>â‰¥40% reduction</strong> in <strong>nonâ€‘HDLâ€‘C</strong> from baseline</td></tr>
            <tr><td>Secondary prevention</td><td><strong>LDLâ€‘C â‰¤2.0 mmol/L</strong> <em>or</em> <strong>nonâ€‘HDLâ€‘C â‰¤2.6 mmol/L</strong></td></tr>
          </tbody>
        </table>
      </article>

      <article class="card" aria-labelledby="monitor-title">
        <div class="kicker">4 Â· Monitoring</div>
        <h3 id="monitor-title">Followâ€‘up</h3>
        <ul>
          <li>Lipids <strong>2â€“3 months</strong> after start/change, then <strong>12 months</strong> (no routine thereafter if stable).</li>
          <li>ALT/AST at 2â€“3 months and 12 months; if &gt;3Ã— ULN â†’ stop; reâ€‘test 4 weeks; do not restart if persistent.</li>
          <li>Assess adverse effects; CK only if symptomatic. If CK &lt;5Ã— ULN â†’ reassure/explore other causes; if &gt;5Ã— ULN â†’ stop.</li>
          <li>Annual medication review: adherence, AE, lifestyle, other RFs (HTN, T2DM). Consider annual lipids.</li>
        </ul>
      </article>

      <article class="card" aria-labelledby="notmet-title">
        <div class="kicker">5 Â· If targets not met</div>
        <h3 id="notmet-title">Optimization &amp; Escalation</h3>
        <ol>
          <li>Confirm <strong>adherence</strong>, <strong>timing</strong>, and <strong>lifestyle</strong>.</li>
          <li><strong>Increase statin</strong> to max tolerated (e.g., atorvastatin stepâ€‘ups to 80 mg; if eGFR &lt;30, agree higher doses with renal specialist).</li>
          <li><strong>Add ezetimibe</strong> if still above target on maximally tolerated statin.</li>
          <li>If on ezetimibe monotherapy (intolerant/contraindicated to statin) â†’ <strong>add bempedoic acid</strong>.</li>
          <li><strong>Consider injectables</strong> per eligibility: <strong>Inclisiran</strong> (siRNA), <strong>PCSK9 mAbs</strong> (alirocumab, evolocumab). In secondary prevention, also consider <strong>icosapent ethyl</strong>.</li>
          <li><strong>Refer</strong> to lipid clinic if persistent elevation despite maximal tolerated therapy.</li>
        </ol>
        <div class="callout" style="margin-top:10px"><span class="dot" aria-hidden="true"></span><div><strong>Statin intolerance toolkit:</strong> pause &amp; rechallenge; switch statin (same intensity); lower dose; alternateâ€‘day or twiceâ€‘weekly regimen (rosuvastatin/atorvastatin have long halfâ€‘lives). Aim for <em>maximum tolerated</em> intensity.</div></div>
      </article>

      <article class="card" aria-labelledby="avoid-title">
        <div class="kicker">6 Â· Avoid (routine use)</div>
        <h3 id="avoid-title">Not Recommended</h3>
        <div class="pill-list" aria-label="Do not offer list">
          <span class="pill">Coenzyme Q10</span>
          <span class="pill">Vitamin D</span>
          <span class="pill">Fibrates (routine)</span>
          <span class="pill">Niacin</span>
          <span class="pill">Bile acid sequestrants</span>
          <span class="pill">Standard omegaâ€‘3s</span>
        </div>
        <p class="tip" style="margin-top:8px">Exception: <strong>Icosapent ethyl</strong> may be added in selected secondary prevention patients per NICE TA.</p>
      </article>

      <article class="card" aria-labelledby="switch-title">
        <div class="kicker">7 Â· Already on a statin</div>
        <h3 id="switch-title">Switching Guidance (Secondary)</h3>
        <ul>
          <li>On low/mediumâ€‘intensity statin (e.g., simvastatin 10â€“40 mg): discuss switch to <strong>atorvastatin 80 mg</strong> (or lower as needed).</li>
          <li>On <strong>simvastatin 80 mg</strong>: encourage switch to atorvastatin 80 mg (myopathy risk is higher on simvastatin 80 mg).</li>
          <li>On <strong>rosuvastatin 10/20/40 mg</strong>: continue rosuvastatin.</li>
        </ul>
      </article>

      <article class="card" aria-labelledby="table-title">
        <div class="kicker">Appendix</div>
        <h3 id="table-title">Statin Intensity (LDLâ€‘C reduction)</h3>
        <details>
          <summary>Expand table</summary>
          <div style="margin-top:10px; overflow:auto">
            <table>
              <thead>
                <tr><th>Drug</th><th>Low</th><th>Medium (31â€“40%)</th><th>High (&gt;40%)</th></tr>
              </thead>
              <tbody>
                <tr><td><strong>Atorvastatin</strong></td><td>â€”</td><td>10 mg (â‰ˆ37%)</td><td>20 mg (â‰ˆ43%), 40 mg (â‰ˆ49%), 80 mg (â‰ˆ55%)</td></tr>
                <tr><td><strong>Rosuvastatin</strong></td><td>â€”</td><td>5 mg (â‰ˆ38%)</td><td>10 mg (â‰ˆ43%), 20 mg (â‰ˆ48%), 40 mg (â‰ˆ53%)</td></tr>
                <tr><td><strong>Simvastatin</strong></td><td>10 mg (â‰ˆ27%)</td><td>20 mg (â‰ˆ32%), 40 mg (â‰ˆ37%)</td><td>80 mg (â‰ˆ42%)*</td></tr>
                <tr><td><strong>Pravastatin</strong></td><td>10 mg (â‰ˆ20%), 20 mg (â‰ˆ24%), 40 mg (â‰ˆ29%)</td><td>â€”</td><td>â€”</td></tr>
                <tr><td><strong>Fluvastatin</strong></td><td>20 mg (â‰ˆ21%), 40 mg (â‰ˆ27%)</td><td>80 mg (â‰ˆ33%)</td><td>â€”</td></tr>
              </tbody>
            </table>
            <p class="tip" style="margin-top:8px">*Use simvastatin 80 mg only in severe hypercholesterolaemia with high CVD risk where benefits outweigh risks.</p>
          </div>
        </details>
        <div class="note" style="margin-top:10px"><strong>Special situations.</strong> HIV (may be underestimated risk; BHIVA suggests offering statin from 40y). CKD: statins permitted; dosing varies by stage. eGFR &lt;30: plan higher doses with renal specialist.</div>
      </article>

    </section>

    <p class="footer">Prepared as a quick reference based on current UK primary care guidance. Use clinical judgement and local pathways. This page is printâ€‘friendly.</p>
  </main>

  <script>
    // Simple theme toggle (persists per session)
    const btn = document.getElementById('toggleTheme');
    const key = 'prefers-light';
    function apply(){
      if(sessionStorage.getItem(key)==='1'){
        document.documentElement.style.colorScheme='light';
        document.body.dataset.theme='light';
      } else {
        document.documentElement.style.colorScheme='dark';
        document.body.dataset.theme='dark';
      }
    }
    btn?.addEventListener('click',()=>{
      sessionStorage.setItem(key, sessionStorage.getItem(key)==='1'?'0':'1');
      apply();
    });
    apply();
  </script>
</body>
</html>
